Skip to main content
. 2009 Nov 27;101(3):646–651. doi: 10.1111/j.1349-7006.2009.01451.x

Figure 3.

Figure 3

 Immunoassaying of estrogen‐related receptor (ERR)‐β (a) and ERRγ (b) in the human prostate. We evaluated 107 cancerous and 92 benign foci. ERRβ and ERRγ immunoreactivities (IRs) were positive in 84 of 92 (91%) and 89 of 92 cases (95%) of benign epithelium, respectively, and in 71 of 106 (67%) and 85 of 106 (80%) cancer cases, respectively. Over 80% and 92% cases of benign foci showed IR scores of ≥5 for ERRβ and ERRγ, respectively, whereas IR scores of ≥5 were obtained in the case of 35% and 55% of patients with cancerous lesions, respectively.